KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
Abstract
Background It has not yet been defined if KRAS has a prognostic value or is a predictive biomarker for the efficacy of erlotinib in advanced pancreatic cancer (PC).Methods AIO-PK0104 was a phase III trial comparing gemcitabine/erlotinib followed by capecitabine with capecitabine/erlotinib followed by gemcitabine in advanced PC. For this post hoc subgroup analysis, biomarker data on the KRAS exon 2 mutation status were correlated with objective response to 1st-line therapy and with overall survival after start of 2nd-line chemotherapy (OSc).Results KRAS codon 12 was mutated in 121 of 173 (70 %) patients. The KRAS status showed no association with objective response (p = 0.40), but KRAS wildtype patients had an improved OS (HR 1.68, p = 0.005). A trend for a survival benefit was also observed during (non-erlotinib containing) 2nd-line chemotherapy, with a HR of 1.47 (p = 0.10) for the OSc.Conclusion This post hoc analysis of AIO-PK0104 supports the assumption that KRAS is rather a prognostic than a predictive biomarker in PC.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There seems to be a consensus that KRAS mutation negatively influences response to EGFR-targeted therapy.
“There seems to be a consensus that KRAS mutation negatively influences response to EGFR-targeted therapy (61, 63).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [63]
Cites
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · see citing works
Amador, M. L., Oppenheimer, D., Perea, S. H., Maitra, A., Cusati, G., Iacobuzio-Donahue, C., Baker, S. D., Ashfaq, R., Takimoto, C. H. M., Forastiere, A. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1036 · Cited by 238 · see citing works
Santos, G. D. C., Dhani, N. C., Tu, D., Chin, K., Ludkovski, O., Kamel‐Reid, S., Squire, J. A., Parulekar, W. R., Moore, M. J., & Tsao, M. (2010) · Cancer · doi:10.1002/cncr.25393 · Cited by 157 · see citing works
Kim, S. T., Lim, D. H., Jang, K.-T., Lim, T., Lee, J., Choi, Y.-L., Jang, H.-L., Yi, J. H., Baek, K. K., Park, S. H., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0269 · Cited by 145 · see citing works
K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer
Chen, H., Tu, H., Meng, Z. Q., Chen, Z., Wang, P., & Liu, L. M. (2010) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2010.05.014 · Cited by 128 · see citing works
Lee, J., Jang, K., Ki, C., Lim, T., Park, Y. S., Lim, H. Y., Choi, D., Kang, W. K., Park, K., & Park, J. O. (2007) · Cancer · doi:10.1002/cncr.22559 · Cited by 127 · see citing works
Heinemann, V., Vehling‐Kaiser, U., Waldschmidt, D., Kettner, E., Märten, A., Winkelmann, C., Klein, S., Kojouharoff, G., Gauler, T. C., von Weikersthal, L. F., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302759 · Cited by 119 · see citing works
Self-citationOgura, T., Yamao, K., Hara, K., Mizuno, N., Hijioka, S., Imaoka, H., Sawaki, A., Niwa, Y., Tajika, M., Kondo, S., et al. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0664-2 · Cited by 112 · see citing works
Systemic treatment of advanced pancreatic cancer
Heinemann, V., Haas, M., & Boeck, S. H. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.004 · Cited by 111 · see citing works
Self-citationBoeck, S. H., Jung, A., Laubender, R. P., Neumann, J. H. L., Egg, R., Goritschan, C., Vehling‐Kaiser, U., Winkelmann, C., von Weikersthal, L. F., Clemens, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.495 · Cited by 107 · see citing works
Self-citationTzeng, C.-W. D., Frolov, A., Frolova, N., Jhala, N. C., Howard, J. H., Vickers, S. M., Buchsbaum, D. J., Heslin, M. J., & Arnoletti, J. P. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9409-5 · Cited by 31 · see citing works
Modest, D. P., Brodowicz, T., Stintzing, S., Jung, A., Neumann, J. H. L., Laubender, R. P., Ocvirk, J., Kurteva, G. P., Pápai, Z., Knittelfelder, R., et al. (2012) · Oncology · doi:10.1159/000339534 · Cited by 27 · see citing works
Self-citationCorrection: Pharmacogenomics of EGFR Inhibitors
(2007) · Cancer Research · doi:10.1158/0008-5472.can-67-16-cor1 · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721 · see citing works
Orth, M., Metzger, P., Gerum, S., Mayerle, J. V., Schneider, G., Belka, C., Schnurr, M., & Lauber, K. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1345-6 · Cited by 488 · see citing works
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360 · see citing works
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
Cicenas, J., Kvederavičiūtė, K., Meskinyte, I., Meškinytė-Kaušilienė, E., Skeberdytė, A., & Cicenas, J. (2017) · Cancers · doi:10.3390/cancers9050042 · Cited by 273 · see citing works
A Comparative Analysis of Individual RAS Mutations in Cancer Biology
Muñoz-Maldonado, C., Zimmer, Y., & Medová, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01088 · Cited by 250 · see citing works
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Heining, C., Horak, P., Uhrig, S., Codó, P., Klink, B., Hutter, B., Fröhlich, M., Bonekamp, D., Richter, D., Steiger, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0036 · Cited by 240 · see citing works
Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma
Saito, Y., Muramatsu, T., Kanai, Y., Ojima, H., Sukeda, A., Hiraoka, N., Arai, E., Sugiyama, Y., Matsuzaki, J., Uchida, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.088 · Cited by 227 · see citing works
KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
Bournet, B., Muscari, F., Buscail, C., Assenat, E., Barthet, M., Hammel, P., Selves, J., Guimbaud, R., Cordelier, P., & Buscail, L. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.18 · Cited by 205 · see citing works
Hadano, N., Murakami, Y., Uemura, K., Hashimoto, Y., Kondo, N., Nakagawa, N., Sueda, T., & Hiyama, E. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.175 · Cited by 171 · see citing works
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
Bournet, B., Buscail, C., Muscari, F., Cordelier, P., & Buscail, L. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.012 · Cited by 164 · see citing works
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 123 · see citing works
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
Conway, J. R. W., Herrmann, D., Evans, T. J., Morton, J. P., & Timpson, P. (2018) · Gut · doi:10.1136/gutjnl-2018-316822 · Cited by 93 · see citing works
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80 · see citing works
Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin
Millis, S. Z., Bryant, D. H., Basu, G. D., Bender, R. P., Vranić, S., Gatalica, Z., & Vogelzang, N. J. (2014) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2014.07.010 · Cited by 68 · see citing works
Shen, H., Lundy, J., Strickland, A. H., Harris, M., Swan, M. P., Desmond, C., Jenkins, B. J., & Croagh, D. G. (2022) · Cells · doi:10.3390/cells11193175 · Cited by 57 · see citing works
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways
Mondal, K., Posa, M. K., Shenoy, R. P., & Roychoudhury, S. (2024) · Cells · doi:10.3390/cells13141221 · Cited by 56 · see citing works
Abdel‐Wahab, R., Varadhachary, G. R., Bhosale, P., Wang, X., Fogelman, D. R., Shroff, R. T., Overman, M. J., Wolff, R. A., & Javle, M. M. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0616-2 · Cited by 50 · see citing works
New targeted therapies in pancreatic cancer
Seicean, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i20.6127 · Cited by 48 · see citing works
Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?
Krantz, B. A., & O'Reilly, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3169 · Cited by 43 · see citing works
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
Turpin, A., Neuzillet, C., Colle, E., Dusetti, N., Nicolle, R., Cros, J. F., de Mestier, L., Bachet, J., & Hammel, P. R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118019 · Cited by 38 · see citing works
Halfdanarson, T. R., Foster, N. R., Kim, G. P., Meyers, J. P., Smyrk, T. C., McCullough, A. E., Ames, M. M., Jaffe, J. P., & Alberts, S. R. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0878 · Cited by 39 · see citing works
Ormanns, S., Heinemann, V., Raponi, M., Isaacson, J. D., Laubender, R. P., Haas, M., Krüger, S., Kleespies, A., Mann, E., Bartosiewicz, M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.023 · Cited by 36 · see citing works
Self-citationLocally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress
Barcellini, A., Peloso, A., Pugliese, L., Vitolo, V., & Cobianchi, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s220971 · Cited by 36 · see citing works
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
Nollmann, F. I., & Ruess, D. A. (2020) · Biomedicines · doi:10.3390/biomedicines8080281 · Cited by 33 · see citing works
Péron, J., Roy, P., Ding, K., Parulekar, W. R., Roche, L., & Buyse, M. E. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.55 · Cited by 32 · see citing works
Ormanns, S., Siveke, J. T., Heinemann, V., Haas, M., Sipos, B., Schlitter, A. M., Esposito, I., Jung, A., Laubender, R. P., Krüger, S., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-624 · Cited by 32 · see citing works
Self-citationFensterer, H., Schade‐Brittinger, C., Müller, H., Tebbe, S., Fass, J., Lindig, U., Settmacher, U., Schmidt, W. E., Märten, A., Ebert, M. P., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt270 · Cited by 32 · see citing works
Critical role of KRAS mutation in pancreatic ductal adenocarcinoma
Fan, Z., Fan, K., Yan, C., Huang, Q., Gong, Y., Cheng, H., Jin, K., Liu, C., Ni, Q., Yu, X., et al. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.19 · Cited by 30 · see citing works
Li, T., Zheng, Y., Sun, H., Zhuang, R., Liu, J., Liu, T., & Cai, W. (2016) · Medical Oncology · doi:10.1007/s12032-016-0777-1 · Cited by 30 · see citing works
Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer
Liu, X., Li, Z., & Wang, Y. (2021) · Advanced Biology · doi:10.1002/adbi.201900236 · Cited by 29 · see citing works
Gu, Y., Ji, Y., Jiang, H., & Qiu, G. (2020) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2020.0078 · Cited by 28 · see citing works
Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers
Cox, V. L., Bhosale, P., Varadhachary, G. R., Wagner‐Bartak, N. A., Glitza, I. C., Gold, K. A., Atkins, J. T., Soliman, P. T., Hong, D. S., & Qayyum, A. (2017) · Radiology · doi:10.1148/radiol.2017152224 · Cited by 26 · see citing works
Genetic alterations shaping tumor response to anti-EGFR therapies
Vaquero, J., Pavy, A., Gonzalez‐Sanchez, E., Meredith, M., Arbelaiz, A., & Fouassier, L. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100863 · Cited by 24 · see citing works
Suzuki, T., Masugi, Y., Inoue, Y., Hamada, T., Tanaka, M. H., Takamatsu, M., Arita, J., Kato, T., Kawaguchi, Y., Kunita, A., et al. (2022) · Cancer Science · doi:10.1111/cas.15398 · Cited by 21 · see citing works
Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts
Krüger, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i31.10769 · Cited by 20 · see citing works
Saito, Y. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14773 · Cited by 19 · see citing works
The role of exosomes in the pathogenesis of pancreatic ductal adenocarcinoma
Robinson, S. M., Fan, L. Y.-N., White, S. A., Charnley, R., & Mann, J. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.03.009 · Cited by 17 · see citing works
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma
Rudloff, U. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2134346 · Cited by 17 · see citing works
Assessing the role of the EGF receptor in the development and progression of pancreatic cancer
Moore, M. J., Cook, N., & Frese, K. K. (2014) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s58925 · Cited by 17 · see citing works
Muyinda, I. J., Park, J. G., Jang, E., & Yoo, B. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105070 · Cited by 16 · see citing works
Mie, T., Sasaki, T., Takeda, T., Okamoto, T., Mori, C., Furukawa, T., Yamada, Y., Kasuga, A., Matsuyama, M., Ozaka, M., et al. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab091 · Cited by 15 · see citing works
Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection
Dai, M., Jahanzaib, R., Liao, Y., Yao, F., Li, J., Teng, X., Chen, K., & Cheng, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1074538 · Cited by 14 · see citing works
Cheng, C., Hou, K., Hsu, C., & Chiang, L. (2023) · Advanced Science · doi:10.1002/advs.202304926 · Cited by 14 · see citing works
Ma, Y., Sender, S., Sekora, A., Kong, W., Bauer, P., Ameziane, N., Al‐Ali, R., Krake, S., Radefeldt, M., Weiß, F. U., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084295 · Cited by 14 · see citing works
Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma
Rubinson, D. A., & Wolpin, B. M. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.04.012 · Cited by 14 · see citing works
Trajectory analysis of drug-research trends in pancreatic cancer on PubMed and ClinicalTrials.gov
Jeong, Y. K., Heo, G. E., Kang, K. Y., Yoon, D. S., & Song, M. (2016) · Journal of Informetrics · doi:10.1016/j.joi.2016.01.003 · Cited by 12 · see citing works
Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC 1 overexpression
Fuereder, T., Stift, J., Kuehrer, I., Stranzl, N., Hoeflmayer, D., Kornek, G. V., & Scheithauer, W. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12329 · Cited by 10 · see citing works
Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma
Sobhani, N., Pittacolo, M., D’Angelo, A., & Marchegiani, G. (2025) · Cancers · doi:10.3390/cancers17040704 · Cited by 10 · see citing works
Pancreatic biomarkers: Could they be the answer?
Lamarca, Á. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i24.7819 · Cited by 9 · see citing works
Czarnecka, A. M., KORZEŃ, P., Nowak-Dement, A., Kukwa, W., Korniluk, J., & Szczylik, C. A. (2015) · Oncology Letters · doi:10.3892/ol.2015.4009 · Cited by 9 · see citing works
Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1
Kikuchi, Y., Shimada, H., Hatanaka, Y., Kinoshita, I., Ikarashi, D., Nakatsura, T., Kitano, S., Naito, Y., Tanaka, T., Yamashita, K., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02430-x · Cited by 8 · see citing works
Sankarasubramanian, S., Pfohl, U., Regenbrecht, C. R. A., Reinhard, C., & Wedeken, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.760705 · Cited by 6 · see citing works
Current Controversies in the Stage-Specific Multidisciplinary Management of Pancreatic Cancer
Katz, M. H. G., Landry, J. C., & Kindler, H. L. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e157 · Cited by 7 · see citing works
Ma, Y., Sender, S., Sekora, A., Kong, W., Bauer, P., Ameziane, N., Krake, S., Radefeldt, M., Al‐Ali, R., Weiß, F. U., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084409 · Cited by 6 · see citing works
Tavano, F., Latiano, A., Palmieri, O., Gioffreda, D., Latiano, T. P., Gentile, A., Tardio, M., Latiano, T. P., Gentile, M., Terracciano, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158436 · Cited by 4 · see citing works
Genetic predisposition for pancreatic cancer
Nakashidze, I., & Ahmad, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819457-7.00008-6 · Cited by 3 · see citing works
Pectasides, D. G., Kotoula, V., Papaxoinis, G., Alexopoulou, Z., Dervenis, C., Samantas, E., Papaparaskeva, K., Charalambous, E., Gkakou, C., Agalianos, C., et al. (2016) · Anticancer Research · doi:10.21873/anticanres.11232 · Cited by 3 · see citing works
Defazio, G., Scolari, F., Fancelli, S., Polvani, S., Lavacchi, D., Picariello, L., Tubita, A., Luconi, M., Antonuzzo, L., Galli, A., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1613773 · Cited by 2 · see citing works
Baechmann, S., Ormanns, S., Haas, M., Krüger, S., Remold, A., Modest, D. P., Kirchner, T., Jung, A., Werner, J., Heinemann, V., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3376-4 · Cited by 2 · see citing works
Self-citationXu, Z., Wang, W., Liu, L., & Lou, W. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188751 · Cited by 2 · see citing works
Lansbergen, M. F., Khelil, M., van Etten‐Jamaludin, F. S., Bijlsma, M. F., & van Laarhoven, H. W. M. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103982 · Cited by 2 · see citing works
Vijayvergia, N., & Cohen, S. J. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.08.01 · Cited by 2 · see citing works
Biomarkers in Pancreatic Cancer
Ansari, D., & Andersson, R. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_31 · Cited by 2 · see citing works
Phytochemical based sestrin2 pharmacological modulators in the treatment of adenocarcinomas
Alausa, A., Victor, U. C., Celestine, U. O., Eweje, I. A., Balogun, T., Adeyemi, R., Olatinwo, M., Ogunlana, A., Oladipo, O., & Olaleke, B. (2021) · Phytomedicine Plus · doi:10.1016/j.phyplu.2021.100133 · Cited by 1 · see citing works
Personalized medicine and new therapeutic approach in the treatment of pancreatic cancer
Azari, H., Nazari, E., Jamialahmadi, H., Khalili‐Tanha, G., Maftooh, M., Hassanian, S. M., Ferns, G. A., Khazaei, M., & Avan, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19142-8.00010-3 · Cited by 2 · see citing works
No Correlation between KRAS Status and Advanced Pancreatic Adenocarcinoma Survival
Ogata, M., Satake, H., Ogata, T., Imai, Y., Hatachi, Y., & Yasui, H. (2017) · Cancer and Clinical Oncology · doi:10.5539/cco.v6n2p45 · Cited by 1 · see citing works
New Therapeutic Targets in RAS Wild-type Pancreatic Cancer
Diab, M. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01242-z · Cited by 1 · see citing works
Zhang, T., Zhu, L., Cai, J., & He, J. (2022) · Open Medicine · doi:10.1515/med-2022-0433 · Cited by 1 · see citing works
Mechanisms of ginseng in pancreatic cancer metastasis
Lin, S., Wang, Z., & Cai, X. (2023) · International Journal of Health Sciences · doi:10.53730/ijhs.v7n3.14490 · Cited by 1 · see citing works
Findet die molekulare Diagnostik Einzug in die Pankreaspathologie?
Sipos, B., & Sperveslage, J. (2013) · Der Pathologe · doi:10.1007/s00292-013-1865-z
Predictive biomarkers for chemotherapies in pancreatic cancer
Dima, A. C., Dima, A., Moldovan, S. C., & Ciurea, M. V. (2015) · Journal of Translational Medicine and Research · doi:10.21614/jtmr-20-3-46
Le point sur hENT1, autres biomarqueurs
Bachet, J. (2015) · ONCOLOGIE · doi:10.1007/s10269-015-2568-2
Exosomes: Navigating a New Route in Pancreatic Cancer
Zhang, S. R., Wang, W. Q., Xu, J., Xu, H. X., Wu, C., Qi, Z. H., Gao, H., Ni, Q. X., Yu, X., & Liu, L. (2017) · Journal of Biomolecular Research & Therapeutics · doi:10.4172/2167-7956.1000149
Molecularly Targeted Therapies in Pancreatic Cancer
Shaib, W. L., & El‐Rayes, B. F. (2017) · Springer eBooks · doi:10.1007/978-3-319-58256-6_12
Mechanisms of ginseng in pancreatic cancer metastasis
Wang, Z., Cai, X., & Lin, S. (2023) · International Journal of Health Sciences · doi:10.53730/ijhs.v7ns1.14490
Varzaru, B., Croitoru, A. E., Sorop, A., Lupescu, I. G., Dima, S., Iacob, R. A., Becheanu, G., & Gheorghe, C. (2026) · Reports — Medical Cases Images and Videos · doi:10.3390/reports9030285
- Authors
- Boeck, S., Jung, A., Laubender, R. P., Neumann, J., Egg, R., Goritschan, C., Ormanns, S., Haas, M., Modest, D. P., Kirchner, T., & Heinemann, V.
- Affiliations
- LMU Klinikum (DE)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Boeck, Stefan
- ORCID
- Venue
- Journal of Gastroenterology
- Published
- 2013-02-23
- Volume
- 48
- Issue
- 4
- Pages
- 544-548
- ISSN
- 0944-1174 (ISSN-L)
- 1435-5922
- OpenAlex
- W2109506970
- Cited by
- 77
- References
- 14
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 8 · 2020: 4 · 2019: 7 · 2018: 4 · 2017: 7 · 2016: 7 · 2015: 7 · 2014: 8 · 2013: 2
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- KRAS mutation, KRAS codon 12, erlotinib, anti-EGFR therapy, advanced pancreatic cancer, predictive biomarkers, prognostic factors, objective response, overall survival, second-line chemotherapy, gemcitabine, capecitabine
- MeSH terms
- Erlotinib Hydrochloride, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Proteins, Pancreatic Neoplasms, Prognosis, Proto-Oncogene Proteins, Quinazolines, Biomarkers, Tumor, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Cross-Over Studies, ras Proteins, Kaplan-Meier Estimate, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
